BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31834883)

  • 1. Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma.
    Choi YB; Son MH; Cho HW; Ma Y; Lee JW; Kang ES; Yoo KH; Her JH; Lim O; Jung M; Hwang YK; Sung KW; Koo HH
    PLoS One; 2019; 14(12):e0225998. PubMed ID: 31834883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
    Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of high-dose
    Lee JW; Kang ES; Sung KW; Yi E; Lee SH; Yoo KH; Koo HH
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 28012219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.
    Illhardt T; Toporski J; Feuchtinger T; Turkiewicz D; Teltschik HM; Ebinger M; Schwarze CP; Holzer U; Lode HN; Albert MH; Gruhn B; Urban C; Dykes JH; Teuffel O; Schumm M; Handgretinger R; Lang P
    Biol Blood Marrow Transplant; 2018 May; 24(5):1005-1012. PubMed ID: 29307718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
    Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity allogeneic stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation.
    Sung KW; Park JE; Chueh HW; Lee SH; Yoo KH; Koo HH; Kim JY; Cho EJ
    Pediatr Blood Cancer; 2011 Oct; 57(4):660-5. PubMed ID: 21681924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
    Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
    Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation.
    Gasior M; Ferreras C; de Paz R; Bueno D; Mozo Y; Sisinni L; Canizales JT; González B; Olivas-Mazón R; Marcos A; Romero AB; Constanzo A; Mirones I; Fernández-Arroyo A; Balas A; Vicario JL; Escudero A; Yuste VJ; Pérez-Martínez A
    Transfusion; 2021 May; 61(5):1505-1517. PubMed ID: 33713461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
    Flaadt T; Ladenstein RL; Ebinger M; Lode HN; Arnardóttir HB; Poetschger U; Schwinger W; Meisel R; Schuster FR; Döring M; Ambros PF; Queudeville M; Fuchs J; Warmann SW; Schäfer J; Seitz C; Schlegel P; Brecht IB; Holzer U; Feuchtinger T; Simon T; Schulte JH; Eggert A; Teltschik HM; Illhardt T; Handgretinger R; Lang P
    J Clin Oncol; 2023 Jun; 41(17):3135-3148. PubMed ID: 36854071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies.
    Zhang F; Sun XF; Li YQ; Zhen ZJ; Zheng HX; Zhu J; Wang QJ; Lu SY; He J; Wang J; Pan K; Cai RQ; Chen Y; Weng DS; Sun FF; Xia JC
    Chin J Cancer; 2013 Dec; 32(12):661-6. PubMed ID: 23706769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using αβ
    Diaz MA; Zubicaray J; Molina B; Abad L; Castillo A; Sebastian E; Galvez E; Ruiz J; Vicario JL; Ramirez M; Sevilla J; González-Vicent M
    Front Immunol; 2019; 10():2504. PubMed ID: 31736949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors.
    Pérez-Martínez A; Fernández L; Valentín J; Martínez-Romera I; Corral MD; Ramírez M; Abad L; Santamaría S; González-Vicent M; Sirvent S; Sevilla J; Vicario JL; de Prada I; Diaz MÁ
    Cytotherapy; 2015 Nov; 17(11):1594-603. PubMed ID: 26341478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
    Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
    Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].
    Yu JP; Cao S; Xin N; An XM; Qi J; Ren XB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1013-8. PubMed ID: 17956681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective observational study of immune reconstitution following transplantation with post-transplant reduced-dose cyclophosphamide from HLA-haploidentical donors.
    Nakamae H; Fujii K; Nanno S; Okamura H; Nakane T; Koh H; Nakashima Y; Nakamae M; Hirose A; Teshima T; Hino M
    Transpl Int; 2019 Dec; 32(12):1322-1332. PubMed ID: 31432532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
    Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.